Uberflip is the world’s #1 Content Experience Platform (CEP). With tools to aggregate all your marketing content, they empower B2B marketing and sales teams to create personalized content experiences to engage accounts, nurture prospects, and convert leads, without the help of IT. It’s their mission to put control back in the hands of marketing teams to deliver high-converting experiences, that put the customer front and center.

C-Suite On Deck

Responsive image

Q&A with Randy Frisch, CMO at Uberflip

MEDIA 7 | September 26, 2019

Randy Frisch, CMO and Co-Founder at Uberflip has led the content experience movement, prompting marketers to think beyond content creation and focus on the experience.  Randy also co-hosts the Conex Show, a weekly podcast featuring top marketers and their strategies and secrets to success. His talks empower marketers with the strategies they need to capture their audiences, prove their worth, and align their vision. MEDIA 7: If I were to say to a bunch of people who know you, ‘Give me three adjectives that best describe you’, what would I hear? RANDY FRISCH: Determined, passionate, caring. M7: From Flipbooks to the world’s first content experience platform in just 6 years. What are some of the top reasons that helped drive Uberflip to where it is now? RF:  We started as a solution that would allow marketers to share content to readers whenever they wanted and on whichever devices. People still want to consume content whenever they want. Think of the way in which we consume video content on Netflix or music content on Spotify. We’ve been successful in large part because we’ve been able to create a product that marketers need, that make it easier for their buyers to become customers. But that hasn’t been enough. The differentiator for us is culture—the values we strive for as an organization (not just the work environment). I’ll share my 3 favourites here: ? H.U.S.T.L.E.: this one stands for Heart, Unique, Skill, Tech, Lean, Entrepreneurial. My co-founder, Yoav Schwartz, and I actually screen new hires for these traits. ? Valuable, Relevant & Consistent: this one comes from the initial definition of Content Marketing (“creating and distributing valuable, relevant and consistent content”) by Robert Rose and Joe Pullizzi at the Content Marketing Institute. It only makes sense that our teams and employees should expect to be valuable,

Read More

Events

Related News

Pharmacy Market

CORRECTING AND REPLACING SENJU PHARMACEUTICAL AND NOVALIQ ENTER INTO LICENSE AGREEMENT FOR NOV03 FOR THE TREATMENT OF DRY EYE DISEASE IN JAPAN

Businesswire | June 15, 2023

news image

Senju Pharmaceutical Co., Ltd., a researched-based Japanese pharmaceutical company focusing the field of ophthalmology, and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique EyeSol® water-free technology, are pleased to announce the closing of a license agreement on Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the first and only prescription treatment for si...

Read More

COVID-19 PANDEMIC: RAPID DELIVERY OF MEDICAL COUNTERMEASURES

Contract Pharma | April 03, 2020

news image

Immeasurable efforts are underway to develop treatments and vaccines to address the COVID-19 pandemic. Numerous discovery methods and technologies are currently being explored in clinical trials such as DNA and RNA-based vaccine candidates, adjuvant platform technologies, recombinant nanoparticles, and monoclonal antibodies, to name a few. As promising therapies begin to emerge, they’ll need to be rapidly scaled up for trials and potential commercialization, which is not without its challe...

Read More

Business Insights, PHARMACY MARKET

MINDMED ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH CATALENT FOR ITS PATENTED ZYDIS® FAST-DISSOLVE TECHNOLOGY FOR USE WITH MM-120

Businesswire | August 07, 2023

news image

Mind Medicine Inc a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has entered into a license agreement with Catalent, a leader in enabling the development and supply of better treatments for patients worldwide, to access Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology. Under the terms of the licensing agreement, Catalent has granted MindMed access to its ...

Read More

Business Insights, PHARMA TECH

SIMULATIONS PLUS ENTERS NEW STRATEGIC COLLABORATION TO DISCOVER ANTICANCER THERAPIES THROUGH ITS AI-DRIVEN DRUG DESIGN TECHNOLOGY

Businesswire | March 29, 2023

news image

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it established a strategic research collaboration with the Sino-American Cancer Foundation (SACF). This collaboration will leverage Simulations Plus’ staff and Artificial Intelligence-driven Drug Design technology in the ADMET Predictor® software platform to support the discovery and design of novel inhibitors of methylenetetrahyd...

Read More
news image

Pharmacy Market

CORRECTING AND REPLACING SENJU PHARMACEUTICAL AND NOVALIQ ENTER INTO LICENSE AGREEMENT FOR NOV03 FOR THE TREATMENT OF DRY EYE DISEASE IN JAPAN

Businesswire | June 15, 2023

Senju Pharmaceutical Co., Ltd., a researched-based Japanese pharmaceutical company focusing the field of ophthalmology, and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique EyeSol® water-free technology, are pleased to announce the closing of a license agreement on Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the first and only prescription treatment for si...

Read More
news image

COVID-19 PANDEMIC: RAPID DELIVERY OF MEDICAL COUNTERMEASURES

Contract Pharma | April 03, 2020

Immeasurable efforts are underway to develop treatments and vaccines to address the COVID-19 pandemic. Numerous discovery methods and technologies are currently being explored in clinical trials such as DNA and RNA-based vaccine candidates, adjuvant platform technologies, recombinant nanoparticles, and monoclonal antibodies, to name a few. As promising therapies begin to emerge, they’ll need to be rapidly scaled up for trials and potential commercialization, which is not without its challe...

Read More
news image

Business Insights, PHARMACY MARKET

MINDMED ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH CATALENT FOR ITS PATENTED ZYDIS® FAST-DISSOLVE TECHNOLOGY FOR USE WITH MM-120

Businesswire | August 07, 2023

Mind Medicine Inc a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has entered into a license agreement with Catalent, a leader in enabling the development and supply of better treatments for patients worldwide, to access Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology. Under the terms of the licensing agreement, Catalent has granted MindMed access to its ...

Read More
news image

Business Insights, PHARMA TECH

SIMULATIONS PLUS ENTERS NEW STRATEGIC COLLABORATION TO DISCOVER ANTICANCER THERAPIES THROUGH ITS AI-DRIVEN DRUG DESIGN TECHNOLOGY

Businesswire | March 29, 2023

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it established a strategic research collaboration with the Sino-American Cancer Foundation (SACF). This collaboration will leverage Simulations Plus’ staff and Artificial Intelligence-driven Drug Design technology in the ADMET Predictor® software platform to support the discovery and design of novel inhibitors of methylenetetrahyd...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Q&A with Randy Frisch, CMO at Uberflip

MEDIA 7 | September 26, 2019

Randy Frisch, CMO and Co-Founder at Uberflip has led the content experience movement, prompting marketers to think beyond content creation and focus on the experience.  Randy also co-hosts the Conex Show, a weekly podcast featuring top marketers and their strategies and secrets to success. His talks empower marketers with the strategies they need to capture their audiences, prove their worth, and align their vision. MEDIA 7: If I were to say to a bunch of people who know you, ‘Give me three adjectives that best describe you’, what would I hear? RANDY FRISCH: Determined, passionate, caring. M7: From Flipbooks to the world’s first content experience platform in just 6 years. What are some of the top reasons that helped drive Uberflip to where it is now? RF:  We started as a solution that would allow marketers to share content to readers whenever they wanted and on whichever devices. People still want to consume content whenever they want. Think of the way in which we consume video content on Netflix or music content on Spotify. We’ve been successful in large part because we’ve been able to create a product that marketers need, that make it easier for their buyers to become customers. But that hasn’t been enough. The differentiator for us is culture—the values we strive for as an organization (not just the work environment). I’ll share my 3 favourites here: ? H.U.S.T.L.E.: this one stands for Heart, Unique, Skill, Tech, Lean, Entrepreneurial. My co-founder, Yoav Schwartz, and I actually screen new hires for these traits. ? Valuable, Relevant & Consistent: this one comes from the initial definition of Content Marketing (“creating and distributing valuable, relevant and consistent content”) by Robert Rose and Joe Pullizzi at the Content Marketing Institute. It only makes sense that our teams and employees should expect to be valuable,

Read More